help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gumbiner, B.
Right arrow Articles by Henry, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gumbiner, B.
Right arrow Articles by Henry, R. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes
*Nutrition
*Obesity
*Weight Control

Journal of Clinical Endocrinology & Metabolism, Vol 70, 1594-1602, Copyright © 1990 by Endocrine Society


ARTICLES

Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus

B Gumbiner, KS Polonsky, WF Beltz, K Griver, P Wallace, G Brechtel and RR Henry
Department of Medicine, University of California, San Diego 92037.

Impairment in pancreatic production of insulin, a cardinal feature of noninsulin dependent diabetes mellitus (NIDDM), was quantified and the kinetics of insulin secretion characterized in six obese individuals with NIDDM before and after weight loss (18.0 +/- 3.0 kg, mean +/- SEM) using a validated mathematical model that employs C-peptide as a marker of the in vivo rate of insulin secretion. The metabolic clearance of C- peptide, assessed by decay analysis after bolus injection of biosynthetic human C-peptide, was not changed by weight loss (0.143 +/- 0.009 L/min.m2 vs. 0.137 +/- 0.010 L/min.m2). Kinetic parameters from each individual's decay curve before and after weight loss were used to derive accurate rates of secretion during the basal (postabsorptive) state, an oral glucose tolerance test and two hyperglycemic clamps. Basal rates of insulin secretion declined 20 +/- 5 pmol/min.m2 (96 +/- 15 to 76 +/- 15 pmol/min.m2, P less than 0.05) concomitant with decreases of 6.9 +/- 0.9 mmol/L in fasting serum glucose (13.7 +/- 1.0 to 6.8 +/- 0.7 mmol/L, P less than 0.05), 60 +/- 14 pmol/L in serum insulin (134 +/- 30 to 74 +/- 15 pmol/L, P less than 0.05), and 0.15 +/- 0.03 pmol/ml in plasma C-peptide (0.67 +/- 0.11 to 0.52 +/- 0.08 pmol/ml, P less than 0.05) concentrations. As expected, weight loss resulted in improved glucose tolerance as measured by the glycemic profiles during the oral glucose tolerance test (P less than 0.05 analysis of variance). The insulin secretory response before weight loss showed a markedly reduced ability to respond appropriately to an increase in the ambient serum glucose. After weight loss, the pancreatic response was more dynamic (P less than 0.05, analysis of variance) and parralleled the moment-to-moment changes in glycemia. Insulin production above basal doubled (11.2 +/- 3.2 to 24.5 +/- 5.8 nmol/6h.m2, P less than 0.05) and peak rates of insulin secretion above basal tripled (55 +/- 16 to 157 +/- 32 pmol/min/m2, P less than 0.05). To assess the beta-cell response to glucose per se and the changes associated with weight reduction, two hyperglycemic clamps were performed at steady state glucose levels in the range characteristic of individuals with severe NIDDM. At a fixed glycemia of 20 mmol/L, average rates of insulin secretion increased almost 2-fold with treatment (161 +/- 41 to 277 +/- 60 pmol/min.m2, P less than 0.05). At an increment of 6 mmol/L glucose above prevailing fasting glucose levels, the average rate of insulin secretion increased 53% (120 +/- 21 to 183 +/- 39 pmol/min.m2, P less than 0.05).(ABSTRACT TRUNCATED AT 400 WORDS)


This article has been cited by other articles:


Home page
Diabetes CareHome page
B. Laferrere, S. Heshka, K. Wang, Y. Khan, J. McGinty, J. Teixeira, A. B. Hart, and B. Olivan
Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux-en-Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes
Diabetes Care, July 1, 2007; 30(7): 1709 - 1716.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. M. Utzschneider, D. B. Carr, S. M. Barsness, S. E. Kahn, and R. S. Schwartz
Diet-Induced Weight Loss Is Associated with an Improvement in {beta}-Cell Function in Older Men
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2704 - 2710.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al.
C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001
Diabetes, January 1, 2004; 53(1): 250 - 264.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Laedtke, L. Kjems, N. Porksen, O. Schmitz, J. Veldhuis, P. C. Kao, and P. C. Butler
Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes
Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E520 - E528.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
K. S. Polonsky, J. Sturis, and G. I. Bell
Non-Insulin-Dependent Diabetes Mellitus -- A Genetically Programmed Failure of the Beta Cell to Compensate for Insulin Resistance
N. Engl. J. Med., March 21, 1996; 334(12): 777 - 783.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society